|
27 Jun 2019 |
SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate Nirogacestat in Combination with Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma
|
|
27 Jun 2019 |
Pliant Therapeutics Reports Positive Results of Phase 1b Clinical Study Supporting Advancement of PLN-74809 for Treatment of Idiopathic Pulmonary Fibrosis
|
|
27 Jun 2019 |
Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints
|
|
27 Jun 2019 |
TARIS Announces Positive Results of Phase 1b Trial of TAR-200 in Muscle Invasive Bladder Cancer
|
|
27 Jun 2019 |
X4 Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Mavorixafor for the Treatment of WHIM Syndrome
|
|
25 Jun 2019 |
Dova Pharmaceuticals Announces European Union Marketing Authorization for DOPTELET® (avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease
|
|
25 Jun 2019 |
Acer Therapeutics Receives Complete Response Letter from U.S. FDA for use of EDSIVO™ (celiprolol) in vEDS Patients
|
|
25 Jun 2019 |
Sound Pharmaceuticals announces positive topline results from the SPI-1005 Phase 2b Meniere's Disease clinical trial
|
|
25 Jun 2019 |
BioPharmX Announces Positive Topline Results from Phase 2b Trial of BPX-04 for Papulopustular Rosacea
|
|
25 Jun 2019 |
Intensity Therapeutics Announces Clinical Collaboration with Merck
|
|
25 Jun 2019 |
Imbrium Therapeutics Advances Insomnia Pipeline Through Initiation of a Phase 2 Study of Potential First-in-Class Molecule for Insomnia Associated with Alcohol Cessation
|
|
25 Jun 2019 |
Aldeyra Therapeutics Announces Results from the SOLACE Trial in Noninfectious Anterior Uveitis
|
|
25 Jun 2019 |
Rodin Therapeutics Announces Positive Phase 1 Results Supporting Continued Development of RDN-929 for Treatment of Neurologic Diseases
|
|
25 Jun 2019 |
Conatus Announces Results from ENCORE-LF and ENCORE-PH Phase 2b Clinical Trials in NASH Cirrhosis
|
|
25 Jun 2019 |
U.S. Food and Drug Administration accepts GSK’s application for ZEJULA (niraparib) in late stage ovarian cancer with priority review
|
|
24 Jun 2019 |
Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder
|
|
24 Jun 2019 |
Applied Therapeutics Announces Initiation of Phase 1/2 Study of AT-007 in Galactosemia
|
|
24 Jun 2019 |
Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia
|
|
24 Jun 2019 |
Epygenix Therapeutics Submits Investigational New Drug Application for EPX-100 to the U.S. FDA for the Treatment of Patients With Dravet Syndrome
|
|
24 Jun 2019 |
Asieris Announces Completion of Enrollment for its US APL-1202 Phase Ib Clinical Trial
|
|
24 Jun 2019 |
AbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive for the t(11;14) Genetic Abnormality
|
|
24 Jun 2019 |
Correvio Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation
|
|
22 Jun 2019 |
Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
|
|
22 Jun 2019 |
European Commission Approves TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer
|
|
22 Jun 2019 |
FDA Approves SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of CF in Children Ages 6-11 Years with Certain Mutations in the CFTR Gene
|
